| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Other Events
Candel Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), sha... |
| 12 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.1 Tipping the balance in favor of the immune system to fight cancer NASDAQ: CADL Corporate Presentation | September 2026 © © 2026 2026 by by C Ca an ndel del T Ther hera ap peu eut ti ic cs s |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026 |
| 24 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Candel Therapeutics, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026. As of April 24, 2026, the record date for the Annual Meeting, there were 73,270,239 outst... |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
This Employment Agreement (“Agreement”) is made between Candel Therapeutics, Inc., a Delaware corporation (the “Company”), and Charles Schoch. (the “Executive”) and is made effective as of June 12, 2026 (the “Effective Date”). |
| 15 May 2026 |
8-K: Regulation FD Disclosure
AUA Investor Call Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer May 15, 2026 NASDAQ: CADL Exhibit 99.1 |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibi... |
| 23 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Candel Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives... |
| 19 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer |
| 05 Dec 2025 |
8-K: Regulation FD Disclosure
Exhibit 99.1 RESEARCH & DEVELOPMENT DAY Virtual Event | December 5, 2025 NASDAQ: CADL |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free surviv... |
| 14 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +4 more
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Triple asterisks denote omissions. |
| 21 Aug 2025 |
8-K: Entry into a Material Definitive Agreement
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition
Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the American Society... |
| 24 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This Securities Purchase Agreement (the “Agreement”) is made as of June 23, 2025, by and among Candel Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature... |
| 23 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Interim CFO elevated to permanent role after demonstrating exceptional financial leadership, guiding the company through major operational and financial milestones |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
Candel Therapeutics, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 17, 2025. As of April 21, 2025, the record date for the Annual Meeting, there were 49,269,668 outst... |
Loading...